Scholar Rock Holding Corporation (SRRK)
SRRK moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How SRRK actually reacts to news — the realized, point-in-time move the market made, measured across 425 labeled events over the last three years with zero look-ahead.
SRRK’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 425 |
| 30-min | 0.00% | 49% | 425 |
| 60-min | -0.16% | 48% | 425 |
| to close | 0.00% | 48% | 423 |
| Middle 50% of SRRK reactions | -1.31% to +1.33% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 425 |
Half of all Scholar Rock Holding Corporation news events land between -1.31% and +1.33% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SRRK reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | -0.21% | 46% | -0.36% |
| Coverage initiations | 31 | -0.17% | 48% | +2.36% |
| Rating reiterations | 106 | -0.45% | 33% | +0.55% |
| Price-target raises | 19 | +0.15% | 53% | -0.55% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how SRRK ranks against every other measured name →
That’s how SRRK usually reacts — get an email when it moves on news →Email me when SRRK moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SRRK's baseline. Nothing else.
Recent SRRK events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) | Press release | Business Wire | -0.87% | +0.79% | |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.01% | +1.21% | |
| Form 8-K Scholar Rock Holding For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -3.64% | -0.79% | |
| Form 8-K Scholar Rock Holding For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | -4.71% | -8.23% | |
| Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA) | Press release | Business Wire | -4.71% | -8.23% | |
| Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial | Press release | Business Wire | +0.81% | -0.92% | |
| Scholar Rock to Present at Upcoming Investor Conferences | Press release | Business Wire | -0.08% | -1.23% | |
| Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan | Press release | Business Wire | +0.45% | +2.02% | |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +1.21% | +0.10% | |
| Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date | Press release | Business Wire | +0.22% | — | |
| Form 10-Q Scholar Rock Holding For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.60% | +4.84% | |
| Form 8-K Scholar Rock Holding For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -3.60% | +4.84% | |
| Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | Business Wire | -3.60% | +4.84% | |
| Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference | Press release | Business Wire | -0.01% | -0.49% | |
| Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA) | Press release | Business Wire | -0.04% | -3.91% | |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.04% | -3.91% | |
| Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026 | Press release | Business Wire | -1.88% | -3.31% | |
| Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD | Press release | Business Wire | +1.46% | +2.59% | |
| Moon Rabbit Expands Client Roster and Senior Leadership, Garners More Industry Recognition | Press release | PR Web | -0.68% | +2.27% | |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.31% | +2.48% | |
| Form 8-K Scholar Rock Holding For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +0.27% | -1.62% | |
| Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | Business Wire | +3.28% | +7.02% | |
| Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference | Press release | Business Wire | +0.00% | +1.49% | |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.28% | -3.76% | |
| Form 10-Q Scholar Rock Holding For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -9.60% | -6.95% | |
| Form 8-K Scholar Rock Holding For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -9.60% | -6.95% | |
| Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights | Press release | Business Wire | -9.60% | -6.95% | |
| Scholar Rock to Present at the BofA Securities 2026 Health Care Conference | Press release | Business Wire | +2.21% | +0.30% | |
| Form ARS Scholar Rock Holding For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.41% | +0.38% | |
| Form DEF 14A Scholar Rock Holding For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | -0.41% | +0.38% | |
| Form DEFA14A Scholar Rock Holding | SEC filing · Form DEFA14A | SEC EDGAR | -0.41% | +0.38% | |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.92% | -3.75% | |
| Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | Business Wire | +0.05% | +1.24% | |
| Form 8-K Scholar Rock Holding For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | -0.80% | +3.13% | |
| Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) | Press release | Business Wire | -0.80% | +3.13% | |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.60% | -0.03% | |
| Form 10-K Scholar Rock Holding For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.55% | -2.06% | |
| Form 8-K Scholar Rock Holding For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -1.55% | -2.06% | |
| Form 8-K/A Scholar Rock Holding For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -2.15% | +3.58% | |
| Form S-8 Scholar Rock Holding | SEC filing · Form S-8 | SEC EDGAR | -1.55% | -2.06% | |
| Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Press release | Business Wire | -1.55% | -2.06% | |
| Scholar Rock to Present at Upcoming Investor Conferences | Press release | Business Wire | +1.27% | +1.16% | |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +1.49% | +1.42% | |
| Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 | Press release | Business Wire | +0.84% | -0.38% | |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.05% | +1.45% | |
| Form 8-K Scholar Rock Holding For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -2.52% | +3.54% | |
| Scholar Rock Highlights 2026 Strategic Priorities | Press release | Business Wire | -2.52% | +3.54% | |
| Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +0.21% | +1.02% | |
| Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.65% | -2.46% | |
| Form 8-K Scholar Rock Holding For: Dec 02 | SEC filing · Form 8-K | SEC EDGAR | +2.04% | +2.70% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SRRK section they belong to.
Where else SRRK is measured.
SRRK earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Moleculin Biotech, Inc. (MBRX) | 426 | -0.21% | 43% |
| Summit Therapeutics Inc. (SMMT) | 426 | +0.03% | 50% |
| Koninklijke Philips N.V. NY Registry Shares (PHG) | 424 | +0.04% | 53% |
| Waters Corporation (WAT) | 424 | +0.05% | 53% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Scholar Rock Holding Corporation's median reaction calculated?
Every labeled SRRK news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 425 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of SRRK's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SRRK's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.